By David Tuller, DrPH On its website, Mahana Therapeutics has listed sixteen gastroenterology and psychology advisors from prominent academic and medical institutions. Companies often add such names to their rosters as a way of signaling their significance and their access to great minds. Sometimes these people are compensated; sometimes not. In many ...

By David Tuller, DrPH Last week I wrote about the recently announced licensing deal between Mahana Therapeutics and King's College London. The deal involves a web-based course of cognitive behavior therapy designed to treat irritable bowel syndrome. In a major study, the reported improvements in symptoms among participants in the ...

By David Tuller, DrPH As I wrote yesterday, Mahana Therapeutics has recently licensed from King’s College London an “innovative digital therapeutic”, a web-based program delivering a course of cognitive behavioral therapy to patients with irritable bowel syndrome. A page on the Mahana site promoting this web-delivered IBS-CBT program furthers the ...

By David Tuller, DrPH Yesterday I sent a freedom-of-information request to King's College London about the recently announced licensing deal it has with Mahana Therapeutics. The deal involves a web-based CBT program for irritable bowel syndrome, which I have written about here and here. This morning I sent a note ...

By David Tuller, DrPH On January 10th, the following information was announced in a press release: Mahana Therapeutics, a digital therapeutics company reimagining the treatment of chronic diseases, today announced that the Company has entered into a licensing and collaboration agreement with King’s College London, a leading research university and ...